Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Other Gross PP&E Adjustments: 2013-2025

Historic Other Gross PP&E Adjustments for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $562.4 million.

  • Amphastar Pharmaceuticals' Other Gross PP&E Adjustments rose 6.14% to $562.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year increase of 6.59%. This contributed to the annual value of $517.0 million for FY2024, which is 5.45% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Other Gross PP&E Adjustments is $562.4 million, which was up 1.06% from $556.5 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Other Gross PP&E Adjustments peaked at $562.4 million during Q3 2025, and registered a low of $409.8 million during Q3 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Other Gross PP&E Adjustments value was $514.1 million (recorded in 2024), while the average stood at $512.3 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Other Gross PP&E Adjustments declined by 1.56% in 2021 and then rose by 15.84% in 2023.
  • Amphastar Pharmaceuticals' Other Gross PP&E Adjustments (Quarterly) stood at $412.1 million in 2021, then climbed by 3.75% to $427.5 million in 2022, then increased by 14.67% to $490.2 million in 2023, then rose by 5.45% to $517.0 million in 2024, then climbed by 6.14% to $562.4 million in 2025.
  • Its last three reported values are $562.4 million in Q3 2025, $556.5 million for Q2 2025, and $541.8 million during Q1 2025.